UK authority warns of Dupixent adverse effects
![Photo: Brendan Mcdermid/Reuters/Ritzau Scanpix](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/14642340/gtxtst/ALTERNATES/schema-16_9/20201124-082557-L-5237x2940ma.jpg)
Regeneron and Sanofi’s atopic dermatitis treatment, the blockbuster Dupixent (dupilumab), has gotten unwanted attention by the UK Medicines and Healthcare products Regulatory Agency (MHRA). On Tuesday, as reported by industry media Endpoints News, the authority warned of new and serious eye reactions from using the drug.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Dupixent might halt "the atopic march," research finds
For subscribers
Leo Pharma's label extension wish granted
For subscribers